Truffle Capital
VC Fund
Paris, France
Truffle Capital is an independent, European venture capital firm focused on disruptive technologies in IT (FinTech and InsurTech) and Life Sciences (BioTech and MedTech). Truffle Capital aims to support the creation and growth of young innovative companies with the potential to become tomorrow’s market leaders. Chaired by Patrick Kron, alongside the company’s founders and CEOs, Philippe Pouletty and Bernard-Louis Roques, Truffle Capital raised over $1 billion and has supported over 75 companies since its creation, in the digital technologies and life sciences sectors. At the end of 2017, Truffle Capital successfully completed the first close of its two new institutional funds, Truffle Financial Innovation Fund and Truffle BioMedTech Fund, as well as the first close of a fund dedicated to the French Reserve Fund (« Fonds de Réserve pour les Retraites » or « FRF »). On May 2019, Truffle Capital is a company of 24 professionals from various nationalities (French, Italian, English, Chinese…), passionated by the trade of financing innovation.
- Total investments:
- 61
- Last investment:
- Lead investor:
- 51%
- Fund size:
- $156M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Truffle Capital invests in
Stages Truffle Capital invests in
Countries Truffle Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 11 contacts → | |||
Round size
- Series A
- $2.2M–$13M
- Series B
- $3.3M–$50M
Investment Focus
Industry
- Biotechnology 13 (21%)
- Financial Services 11 (18%)
- Health Care 9 (15%)
- Software 8 (13%)
- FinTech 7 (11%)
Stage
- Series A 14 (23%)
- Funding Round 14 (23%)
- Series B 11 (18%)
- Seed 6 (10%)
- Venture - Series Unknown 4 (7%)
Country
- France 27 (44%)
- United States 4 (7%)
- Belgium 2 (3%)
- Switzerland 2 (3%)
- The Netherlands 2 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Antoine Pau
Partner
|
Partner | Total investments: 0 | Find email | |
Faranaz Auliar
Philippe Pouletty Executive Assistant
|
Philippe Pouletty Executive Assistant | Total investments: 0 | Find email | |
Jean-Claude Caducal
CEO Circle, Life Sciences
|
CEO Circle, Life Sciences | Total investments: 0 | Find email | |
Michel Finance
Venture Partner
|
Venture Partner | Total investments: 2 | Find email | |
Miguel Sieler
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Cachet is a financial services marketplace on a mission to create a better, healthier platform economy. It gives gig workers [in ride-hailing] a single insurance policy across platforms that’s fairly priced, personalised and easy to use. With services that help platform workers reduce their costs, improve their net earnings and feel empowered intheir lifestyle, we make the platform economy better for everyone. | Venture - Series Unknown / Oct 13, 2026 | ||
| Géocorail développe et commercialise un produit innovant faisant travailler la mer à la protection du littoral : le Géocorail®. Ce procédé électrochimique breveté innovant consiste à créer une roche artificielle permettant de protéger les ouvrages marins et de lutter contre l’érosion du littoral. | $8.5M / Venture - Series Unknown / Jun 08, 2026 | ||
| Hydrosat is a deep-tech company using thermal satellite data and AI to address society's most urgent challenges. We provide geospatial intelligence for food production, security, and natural resource management. | $60M / Series B / Jan 15, 2026 | ||
| AlgoTrader is the global institutional leader in algorithmic trading and execution infrastructure for both digital and traditional assets. With its advanced software solutions, AlgoTrader gives banks, hedge funds, brokers, crypto funds and other financial institutions an end-to-end platform for best execution and event-driven alpha generation. Thecompany's offering includes WIRESWARM, a digital asset trading and connectivity platform for banks and brokers, AlgoTrader QUANT, an end-to-end quantitative trading solution with automated trade signal generation and order execution, and AlgoTrader OEMS, a state-of-the-art Order and Execution Management System for systematic and discretionary buy-side institutions with managed connectivity to over 400 liquidity venues. AlgoTrader’s interdisciplinary team of quantitative strategy developers, senior software engineers and financial and crypto experts is shaping institutional trading. Founded in Switzerland and based in Zurich, New York and Singapore, AlgoTrader operates globally. | $16.9M / Series B / Nov 12, 2024 | ||
| Dgpays are into fintech which provides end-to-end payment system for Banks, E-Money Institutions, Telecom and Transportation Operators. | $50M / Series B / Feb 27, 2024 | ||
| Levenue is built to help European founders with unlocking that value, positioning revenue as a new asset class. We are creating the largest European revenue-based finance marketplace that transforms recurring revenues into upfront cash instantly. We connect institutional investors with founders/ CFO’S on our platform. So that founders can getback to what really matters, focusing on their company. We provide recurring revenue companies with growth capital without diluting shareholders, or without the need for high consumer discounts, by leveraging on revenues. | $8.7M / Series A / Nov 15, 2023 | ||
| Obat supplies contractors and independent contractors with invoicing software. The tool is constantly changing depending on input from customers and partners. | $12.8M / Series A / Nov 09, 2023 | ||
| MoneyTrack is a global, decentralized blockchain platform for Directed Money. | $2.2M / Series A / Jan 12, 2023 | ||
| Obat supplies contractors and independent contractors with invoicing software. The tool is constantly changing depending on input from customers and partners. | $6M / Seed / Sep 18, 2022 | ||
| Abivax is a clinical-stage biotechnology company, that mobilizes the body’s natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Their aim is to use Abivax's drug development platforms to provide novel and effective treatments to patients with large unmet needs in these therapeutic areas. | $49M / Post-IPO Equity / Sep 02, 2022 | ||
| See all 61 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Truffle Capital invest in?
Truffle Capital invests primarily in Biotechnology, Financial Services and Health Care startups, most often at Series A and Funding Round stage. Most of the 61 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Truffle Capital invest in?
Truffle Capital typically joins rounds of $2.2M–$13M at Series A and $3.3M–$50M at Series B. These are whole funding-round sizes, not Truffle Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Truffle Capital took part in.
How do I contact Truffle Capital?
Public channels for Truffle Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Truffle Capital?
The team at Truffle Capital includes Antoine Pau (Partner), Faranaz Auliar (Philippe Pouletty Executive Assistant) and Jean-Claude Caducal (CEO Circle, Life Sciences), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
